The European Commission has granted marketing authorization in the European Union (EU) for new Eylea™ 8 mg (aflibercept 8 mg) for the treatment of neovascular (wet) age-related macular degeneration ...

The European Commission (EC) has approved Eylea 8 mg with extended treatment intervals of up to 6 months in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) / ...

Berlin, January 22, 2024 – Bayer today announced Nelson Ambrogio as the new Head of the Radiology Business at its Pharmaceuticals Division, effective April 1, 2024. He will report to Stefan Oelrich, ...

Committee for Medicinal Products for Human Use (CHMP) opinion is based on the findings from the pivotal clinical trials PULSAR in neovascular (wet) age-related macular degeneration (nAMD) and PHOTON ...

For people living with type 1 diabetes (T1DM), kidney health is an important part of lifelong care. Chronic kidney disease, or CKD, can develop gradually and may progress for years before symptoms ...

First Phase III results from the clinical development program QUANTI on investigational MRI contrast agent gadoquatrane presented as late-breaking data during a scientific session at the 2025 European ...

Bayer believes that innovation in healthcare extends beyond medicines and technologies. It also includes empowering healthcare professionals with the knowledge, skills, and tools needed to thrive in ...

Exclusive license agreement includes rights to develop and commercialize Cedilla’s CyclinE1/CDK2 inhibitors / Assets are currently in pre-clinical development with potential to serve patients with ...

Bayer is using multi-stacked virus-resistant genes to bring more durable protection against ToBRFV mutations / Developed through advanced conventional breeding techniques, new hybrids will be ...

The newest LifeHub in the Bayer network will connect the company more closely to the German innovation ecosystem of scientists, researchers, decision makers, and entrepreneurs / Focus lies on dialogue ...

Kent Kalcevic’s story shows how a fifth-generation farmer responds to dry conditions by focusing on soil health, technology and the future of agriculture. His family has been operating a farm east of ...

Effective April 15, 2025, he will succeed Dr. Robert Reiter who has decided to retire after 27 years with the company and 34 years in the industry / Dr. Mike Graham has profound expertise in R&D and ...